Exact Sciences Corp. (NASDAQ: EXAS) today announced that, in support of
the Company's continued growth plans, it has issued restricted stock
units covering a total of 125,661 shares of common stock to 166 new
non-executive employees under its previously announced inducement grant
program. The restricted stock unit awards vest in four equal annual
installments beginning on the first anniversary of the grant date. The
Company is making this announcement as required by NASDAQ rules.
About Exact Sciences
Exact Sciences Corp. (NASDAQ: EXAS) is a molecular diagnostics company
focused on the early detection and prevention of colorectal cancer. The
company has exclusive intellectual property protecting its noninvasive,
molecular screening technology for the detection of colorectal cancer.
Cologuard is included in the colorectal cancer screening guidelines of
the American Cancer Society and stool DNA is included in the U.S.
Multi-Society Task Force on Colorectal Cancer. For more information,
please visit the company's website at www.exactsciences.com,
follow us on Twitter @ExactSciences or find us on Facebook.
Copyright Business Wire 2015